InspireMD Inc. (NSPR)
Stock Price:
$0.423 USD
-0.007 (-1.52%)
Updated Aug 14, 2020 2:44 PM EDT - Market open
Key Info
| Market Cap |
6.47M |
| Revenue (ttm) |
4.34M |
| Net Income (ttm) |
-9.09M |
| Shares Out |
33.36M |
| EPS (ttm) |
-2.90 |
| PE Ratio |
n/a |
| Forward PE |
11.70 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 14, 2020 |
| Last Price |
$0.423 |
| Previous Close |
$0.429 |
| Change ($) |
-0.007 |
| Change (%) |
-1.52% |
| Day's Open |
0.420 |
| Day's Range |
0.417 - 0.428 |
| Day's Volume |
592,758 |
| 52-Week Range |
0.386 - 5.300 |
More Stats
| Market Cap |
6.47M |
| Enterprise Value |
6.94M |
| Earnings Date (est) |
Nov 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
33.36M |
| Float |
4.31M |
| EPS (basic) |
-0.9 |
| EPS (diluted) |
-2.90 |
| FCF / Share |
-0.58 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
185,348 |
| Short Ratio |
0.07 |
| Short % of Float |
0.56% |
| Beta |
2.21 |
| PE Ratio |
n/a |
| Forward PE |
11.70 |
| P/FCF Ratio |
n/a |
| PS Ratio |
1.49 |
| PB Ratio |
1.16 |
| Revenue |
4.34M |
| Operating Income |
-8.97M |
| Net Income |
-9.09M |
| Free Cash Flow |
-7.38M |
| Net Cash |
-476,000 |
| Net Cash / Share |
-0.03 |
| Gross Margin |
17.42% |
| Operating Margin |
-206.68% |
| Profit Margin |
-275.40% |
| FCF Margin |
-170.14% |
| ROA |
-62.40% |
| ROE |
-193.29% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
2.00
Current: $0.423
High
2.00
Target: 2.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 3.72 | 3.60 | 2.76 | 1.89 | 2.31 | 2.82 | 4.87 | 5.35 | 6.00 | 4.95 |
| Revenue Growth | 3.33% | 30.42% | 45.78% | -18.01% | -18.03% | -42.17% | -8.9% | -10.91% | 21.32% | - |
| Gross Profit | 0.76 | 1.00 | 0.59 | 0.10 | -0.30 | 0.78 | 2.59 | 2.50 | 2.99 | 2.25 |
| Operating Income | -9.82 | -7.61 | -8.23 | -7.65 | -14.49 | -23.70 | -15.07 | -17.55 | -13.73 | -3.22 |
| Net Income | -10.04 | -7.24 | -8.44 | -8.46 | -15.59 | -25.10 | -29.26 | -17.60 | -14.67 | -3.42 |
| Shares Outstanding | 2.09 | 0.46 | 0.01 | - | - | - | - | - | - | - |
| Earnings Per Share | -4.80 | -16.67 | -1,749.00 | -10,386.00 | -97,742.39 | -310,203.01 | -608,155.41 | -455,022.75 | -415,645.78 | -122,506.13 |
| Operating Cash Flow | -9.81 | -7.61 | -8.13 | -7.50 | -11.60 | -19.36 | -10.30 | -8.58 | -6.00 | -2.71 |
| Capital Expenditures | -0.28 | -0.07 | -0.26 | -0.05 | -0.02 | -0.13 | -0.20 | -0.28 | -0.10 | -0.08 |
| Free Cash Flow | -10.09 | -7.67 | -8.39 | -7.54 | -11.61 | -19.50 | -10.50 | -8.86 | -6.10 | -2.79 |
| Cash & Equivalents | 5.51 | 9.38 | 3.71 | 7.52 | 3.26 | 6.30 | 14.91 | 10.32 | 5.19 | 0.89 |
| Total Debt | 0.65 | - | - | 2.68 | 5.25 | 8.90 | - | 5.02 | 0.09 | 1.49 |
| Net Cash / Debt | 4.86 | 9.38 | 3.71 | 4.84 | -1.99 | -2.60 | 14.91 | 5.30 | 5.09 | -0.61 |
| Assets | 9.88 | 12.29 | 6.11 | 9.41 | 5.69 | 11.46 | 20.75 | 16.01 | 10.47 | 4.36 |
| Liabilities | 4.50 | 3.53 | 3.11 | 5.37 | 8.64 | 14.25 | 4.64 | 10.63 | 3.71 | 5.27 |
| Book Value | 5.38 | 8.76 | 2.73 | 4.05 | -2.95 | -2.79 | 16.10 | 5.39 | 6.75 | -0.91 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
InspireMD Inc. |
| Country |
Israel |
| Employees |
48 |
| CEO |
Marvin L. Slosman |
Stock Information
| Ticker Symbol |
NSPR |
| Stock Exchange |
NYSE American |
| Sector |
Healthcare |
| Industry |
Medical Devices |
| Unique Identifier |
NYSEAMERICAN: NSPR |
Description
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms in order to seal the aneurysms. InspireMD, Inc. distributes its products in Europe, Latin America, the Middle East, and Asia. The company is headquartered in Tel Aviv, Israel.